RxDoctor Payments Data

Alfred Chance, MD

Internal Medicine · Mobile, ALNPI 1124035795

Payments from drug & device makers

$404in general payments, 2019–2025

Across 19 payments — averaging $21.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$108
  • Lilly USA, LLC$78
  • Scilex Pharmaceuticals Inc.$73
  • AstraZeneca$46
  • Otsuka America Pharmaceutical, Inc.$44
  • Acadia Pharmaceuticals Inc$22
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$404 in reported general payments places this provider in the 50th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$46,227
Medicare patients
142
Services billed
392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate64$255,126
EliquisApixaban407$124,892
HumiraAdalimumab15$109,722
TrulicityDulaglutide60$53,718
NuplazidPimavanserin Tartrate12$41,017
NuedextaDextromethorphan Hbr/Quinidine57$37,972
Breo ElliptaFluticasone/Vilanterol74$32,040
JardianceEmpagliflozin69$21,117
AustedoDeutetrabenazine13$19,279
Atorvastatin Calcium708$18,827
Olanzapine263$16,413
Memantine Hcl269$16,285
EntrestoSacubitril/Valsartan47$16,162
LantusInsulin Glargine,hum.Rec.Anlog160$12,510
Spiriva RespimatTiotropium Bromide22$12,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$14$255,12664 claims
Lilly USA, LLCTrulicity, Olanzapine$78$70,131323 claims
Acadia Pharmaceuticals IncNuplazid$22$41,01712 claims
Avanir Pharmaceuticals, Inc.Nuedexta$108$37,97257 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →